Treatment duration approximately 2 years and 6 months: until reimbursement of avalglucosidase alfa in France or until December 2024, whichever comes first
This long-term open label safety and efficacy study is intended to follow up, and to provide post-trial access to enzyme replacement therapy (ERT) with avalglucosidase alfa to patients with Pompe disease in France who have completed Study EFC14028, LTS13769, or ACT14132, from market authorization until reimbursement of avalglucosidase alfa in France or until December 2024, whichever comes first.~- Study visit frequency: every 2 weeks